Skip to main content

Table 1 Characteristics and outcomes of patients with community-onset bacteremic BTIs with and without anaerobic coverage as the definitive therapy

From: Anaerobic coverage as definitive therapy does not affect clinical outcomes in community-onset bacteremic biliary tract infection without anaerobic bacteremia

Variables Total (N = 87) Definitive therapy without anaerobic coverage (N = 24) Definitive therapy with anaerobic coverage (N = 63) p value
Age (mean) 73.4 ± 13.9 71.5 ± 14.2 74.2 ± 13.9 0.419
Male sex 65(74.7) 18(75) 47 (74.6) 0.970
Underlying disease
 Diabetes mellitus 31(35.6) 8(33.3) 23(36.5) 0.782
 Congestive heart failure 30(34.5) 3(12.5) 17(27.0) 0.151
 Liver cirrhosis 4(4.6) 3(12.5) 1(1.6) 0.062
 Chronic obstructive pulmonary diseases 10(11.5) 1(4.2) 9(14.3) 0.186
 Chronic renal failure 68(78.2) 14(58.3) 54(85.7) 0.006
 Malignancy 35(40.2) 9(37.5) 26(41.3) 0.749
Healthcare-associated bacteremia 38(43.7) 8(33.3) 30(47.6) 0.230
Microbiology
E.coli 48(55.2) 16(66.7) 32(51.6) 0.207
K. pneumoniae 20(23.0) 2(8.7) 18(28.6) 0.053
 Othersa 28(32.2) 6(25.0) 22(34.9) 0.38
Biliary abnormalities
 Malignant obstruction 31(35.6) 7(29.3) 24(38.1) 0.437
 Benign stricture 2(2.3) 0(0.0) 2(3.2) 1.000
 Choledocholithiasis 52(59.8) 15(62.5) 37(58.7) 0.749
 Unknown 2(2.3) 2(8.3) 0(0.0) 0.074
Pitt bacteremia score(mean) 1.2 ± 1.5 1.5 ± 1.8 1.1 ± 1.3 0.270
Biliary drainageb 73(83.9) 20(83.3) 53(84.1) 0.928
Appropriate empirical therapy 65(74.7) 18(75.0) 47(74.6) 0.970
Empirical therapy with anaerobic coverage 68(78.2) 12(50) 56(88.9) < 0.001
Clinical outcome
 Clinical improvement 70(80.5) 20(83.3) 50(79.4) 0.677
 Treatment failure 17(19.5) 4(16.7) 13(20.6) 0.677
 Relapse 13(14.9) 3(12.5) 10(15.9) 0.693
 28-day mortality 4(4.6) 1(4.2) 3(4.8) 1.000
Duration (days) of anaerobic coverage 9.1 ± 6.0 2.2 ± 1.8 11.8 ± 4.7 < 0.001
Total duration (days) of antibiotic use 13.2 ± 5.2 13.1 ± 5.7 13.2 ± 5.0 0.913
  1. aOther pathogens included Enterococcus spp., Streptococcus spp., Enterobacter spp., Pseudomonas spp., Raoultella spp., Acinetobacter spp., Citrobacter spp., Aeromonas spp.
  2. bDrainage included endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangial drainage, percutaneous transhepatic gallbladder drainage, surgical drainage and indwelling stent